StockSelector.com
  Research, Select, & Monitor Sunday, September 23, 2018 11:45:38 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Melinta Therapeutics, Inc.$4.50($.05)(1.10%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Melinta Therapeutics, Inc. has an overall rank of 7060 out of 7243 stocks based on 7 positive rankings and 8 negative rankings.

Positive Rankings
Up Ratings Revision
During the past month, the average analyst's rating or recommendation has increased. Among companies that have been upgraded within the past month, Melinta Therapeutics is ranked 65.
Estimated Revenue Growth
Melinta Therapeutics rank is 130
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Melinta Therapeutics is ranked 740.
Low Put/Call
Melinta Therapeutics has a low Put/Call ratio of 0.52 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Melinta Therapeutics is ranked 1089.
10 Day Gain
Melinta Therapeutics rank is 1813
Price-to-Book
Melinta Therapeutics rank is 2308
Debt-to-Equity
Melinta Therapeutics rank is 2404
Negative Rankings
90 Day Loss
Melinta Therapeutics rank is 326
Negative Net Margin
Melinta Therapeutics rank is 401
Negative ROE
Melinta Therapeutics rank is 420
High vPut/Call
Melinta Therapeutics has a high Put/Call ratio of 1.97 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Melinta Therapeutics is ranked 422.
Negative Cash Growth
Melinta Therapeutics rank is 575
Negative ROA
Melinta Therapeutics rank is 672
Down EPS Surprise
Melinta Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
Price-to-Sales
Melinta Therapeutics rank is 1073







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.